Skip to main content
54°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
20.13
+0.56 (+2.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte Inc
< Previous
1
2
3
4
5
Next >
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
February 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
January 23, 2023
From
Exagen Inc.
Via
GlobeNewswire
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 15, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Third Quarter 2022 Financial Results
November 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
November 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 27, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
October 25, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
October 24, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
October 18, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
October 13, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
September 22, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 13, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
September 11, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
September 07, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
August 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
August 29, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 11, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Second Quarter 2022 Financial Results
August 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
July 20, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
July 14, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
July 13, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
June 27, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
June 20, 2022
From
Veracyte, Inc.
Via
Business Wire
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
June 03, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
May 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
May 16, 2022
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.